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Katie Mendez, RN
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UNDERLYING
PATHOLOGY

INTRODUCTION
According to The World Health
Organization, depression is the fourth
leading cause of total disease burden and
the leading cause of disability worldwide.
In the United States, results from the
National Health and Nutrition
Examination Survey reflect a 16.2%
lifetime depression prevalence.
Symptoms of depression can range from
mild to severe and can be episodic or
chronic. Depression has a high rate of
comorbidity with multiple chronic
diseases and other mental health
disorders, predominately anxiety.
Unfortunately, few Americans diagnosed
with depression actually receive
sufficient treatment and symptom
management. Previous research has
shown that individuals are more likely to
seek treatment for depression in a
primary care setting than a mental health
specialty clinic, especially individuals of
ethnic and racial minority populations.
Approximately 50% of individuals
suffering from depression are receiving
no pharmacological or
psychotherapeutical services (Shim,
Baltrus, Ye, & Rust, 2011). Current
research is investigating the role of brainderived neurotrophic factor (BDNF) and
the hypothalamic-pituitary-adrenal axis
(HPA), and its role in the diagnosis,
progression, and treatment of depression
(U.S. National Library of Medicine [NLM],
2000, para. 2). This research provides
insight into the mechanism of action of
antidepressant medications and expands
the available knowledge to facilitate more
thorough patient education regarding the
benefits of treatment.

Bacha, E. (2012). Depression in Men
[Photograph]. Retrieved from
http://enahams38.blogspot.com/2012/09/
depression-in-men.html

Sakata, K. (2011). Neurobiology of
Depression [Photograph]. Retrieved from
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PATHOLOGICAL
PROCESS
According to The World Health
Organization, depression is the fourth
leading cause of total disease burden
and the leading cause of disability
worldwide. In the United States, results
from the National Health and Nutrition
Examination Survey reflect a 16.2%
lifetime depression prevalence.
Symptoms of depression can range from
mild to severe and can be episodic or
chronic. Depression has a high rate of
comorbidity with multiple chronic
diseases and other mental health
disorders, predominately anxiety.
Unfortunately, few Americans
diagnosed with depression actually
receive sufficient treatment and
symptom management. Previous
research has shown that individuals are
more likely to seek treatment for
depression in a primary care setting
than a mental health specialty clinic,
especially individuals of ethnic and
racial minority populations.
Approximately 50% of individuals
suffering from depression are receiving
no pharmacological or
psychotherapeutical services (Shim,
Baltrus, Ye, & Rust, 2011). Current
research is investigating the role of
brain-derived neurotrophic factor
(BDNF) and the hypothalamic-pituitaryadrenal axis (HPA), and its role in the
diagnosis, progression, and treatment of
depression (U.S. National Library of
Medicine [NLM], 2000, para. 2). This
research provides insight into the
mechanism of action of antidepressant
medications and expands the available
knowledge to facilitate more thorough
patient education regarding the benefits
of treatment.

The neurobiology mechanisms of
depression are not well known but are
hypothesized to be a combination of
genetic and environmental factors. For
the past fifty years the Monoamine
Hypothesis of Depression has been the
leading explanation. This hypothesis is
based on a deficit or imbalance of
monoamine neurotransmitters;
norepinephrine, serotonin, and
dopamine. The enhancing effects of
antidepressants on the monoaminergic
system provides the primary support
for this hypothesis. Clinical response to
antidepressants only occurs after weeks
to months of treatment and only
chronic use is effective. This
phenomenon suggests that lasting
changes in gene expression are
required for antidepressants efficacy
(Masi & Brovedani, 2011). Research
within the last decade has expanded the
earlier Monoamine Hypothesis to
integrate the gene transcription
element which has been found to play a
critical role in the diagnosis and
treatment of depression. The
Monoamine Hypothesis of Gene
Expression has pointed to the role of
neurotrophic factors, particularly brainderived neurotrophic factor. The
Neurotrophic Hypothesis of Neuronal
Development further explores the role
of BDNF in neuronal development,
plasticity, and survival (Aricioglu &
Gumru, 2012).
BDNF is initially synthesized as a
precursor (prepro-BDNF) which then
cleaves to pro-BDNF and the mature
form of BDNF (mBDNF). mBDNF then
binds with two different receptors at
the target cell, TrkB and p75. mBDNF’s
trophic effects are mediated by TrkB
receptor activation which is involved
with promoting synaptic plasticity and
regulating protein synthesis-dependent
long-term potentiation, while pro-BDNF
binds with high affinity to p75
receptors which are linked to the
induction of apoptosis (Hill, 2012).

BDNF is present in multiple tissues
and cell types; skeletal muscles, kidneys,
retinas, motor neurons, the prostate, and
the central nervous system. The highest
concentration of BDNF is found in the
dentate gyrus of the hippocampus, the
cerebral cortex, and the basal forebrain.
The majority of neurons are formed
prenatally but parts of the adult brain,
particularly the hippocampus and the
olfactory bulb, retain the ability to grow
new neurons from neural stem cells,
neurogenesis. BDNF is one of the most
active neurotrophins involved in
stimulating and controlling neurogenesis.
Patients with depression are found to
have a reduction of hippocampal volume,
decreased BDNF expression, and thus
decreased neurogenesis (Masi &
Brovedani, 2011).
It is unclear whether reduced
hippocampal volume is a result of
depression or a cause but growing
research supports a direct link between
decreased BDNF and depression. One of
the hypothetical frameworks which links
decreased BDNF with depression is the
Hypothalamic-Pituitary-Adrenal Axis
Abnormalities and Brain-Derived
Neurotrophic Factor Hypothesis. This
hypothesis provides further insight into
the environmental factors involved in
depression. Acute and chronic stress can
induce hyperactivity of the hypothalamicpituitary-adrenal (HPA) axis with a
resultant increase in glucocorticoid levels
which reduces the expression of BDNF
and interferes with its binding to the
TrkB receptor, thus decreasing BDNF
signaling. The HPA axis is regulated via a
negative feedback loop, increased
glucocorticoids in the bloodstream cause
an inhibitory response in the
hypothalamus and the pituitary gland
which decreases the synthesis of
corticotropin releasing hormone and
adrenocorticotropic hormone. The
hippocampus also plays a role in this
negative feedback loop by signaling the
HPA axis to down-regulate cortisol
production. The hippocampus has a high
density of glucocorticoid receptors and
increased cortisol levels have been shown
to lead to neurotoxicity in this area. This
perpetuates a vicious cycle of continual
HPA axis hyperactivation and
hippocampal damage (Kunugi, Hori,
Adachi, & Numakawa, 2010).

SIGNIFICANCE OF
PATHOLOGY
Research has found that BDNF
expression in the hippocampus is
increased with chronic and not with acute
antidepressant treatment (Kunugi et al.,
2010). BDNF levels are decreased in
patients with depression and also
correlate with the severity of the
depression. BDNF levels after chronic
antidepressant treatment increase to the
same level found in healthy, nondepressed individuals. Due to the central
role of BDNF in depression, health care
providers may opt to obtain baseline
BDNF levels prior to and throughout
treatment to determine efficacy (Kurita,
Nishino, Kato, Numata, & Sato, 2012).
Gender specific considerations may also
warrant further investigation, estrogen
receptors co-localize with BDNFsynthesizing neurons and induce BDNF
expression therefore, females with
estrogen deficiencies or of postmenopausal age may present uniquely
(Kunugi et al., 2010). Additional
therapies that have been reported to
increase BDNF levels are; zinc
supplementation, omega-3 fatty acids,
regular exercise, and caloric restrictions
(Ranjbar et al., 2014). The HPA-BDNF
link also provides useful insights into the
benefits of stress reduction in the
treatment of depression, thus regular
exercise may serve a dual purpose in
increasing BDNF and decreasing stress.
Psychotherapy and a daily relaxation
regimen can also be very useful as
adjunct therapies.

Nestler, E. (2002). Neurotrophic
Mechanisms in Depression [Photograph].
Retrieved from
http://www.sciencedirect.com/science/artic
le/pii/S0896627302006530

IMPLICATIONS FOR
NURSING CARE
Educate Patients Regarding:
•The importance of antidepressant
medication compliance and continual
treatment
•The dual benefits of regular
exercise
•The benefits of a healthy diet
within an appropriate caloric range
•The role stress plays in depression
and the benefits of adding a form of
relaxation therapy to their daily routine
•The basic pathological process
involved in depression to assist the
patient with better understanding of the
disease process and appropriate coping
mechanisms
.

Chokka, P. (2013). Management of
Depression [Photograph]. Retrieved from
http://omicsgroup.org/journals/JDAimag
es/2167-1044-2-141-g002.html

CONCLUSION
The pathophysiology of depression
plays an integral role in explaining the
efficacy of treatment and additional
physiological mechanisms that may be
involved. The effects of BDNF levels in
depressed patients may provide
resources for additional screening tests,
diagnostic tests, and tests for
monitoring treatment efficacy. The HPA
axis functionality may also provide
additional testing tools to determine
what role stress, current or past, is
contributing to the patients disease
process. Lastly, the inclusion of
education regarding symptoms,
contributing factors, additional
therapies, and lifestyle modifications
may lead to better disease management.
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